News Search Results
Oct 22, 2025, 07:00 ET Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer
and CEO of Millendo Therapeutics. She has held board roles at both emerging and publicly traded companies and currently serves on the board of Biotechnology Innovation Organization (BIO) and other organizations. As CEO, Julia will focus on steering the company as it enters a new stage of growth. Richard
More news about: Basking Biosciences Inc.
Oct 22, 2025, 06:30 ET Flagship Pioneering Unveils Expedition Medicines to Expand the Boundaries of Small Molecule Medicines with Generative Design
Sana Biotechnology,
More news about: Flagship Pioneering
Oct 22, 2025, 05:57 ET Taiwan Showcases Evidence-Based TCM at CPHI Frankfurt 2025
traditional remedies for daily use. Grape King Bio integrates herb-based TCM formulations with biotechnology-driven mushroom innovations, creating nutraceuticals that support immune health and metabolism. "Taiwan has demonstrated
More news about: Taiwan Institute of Economic Research
Oct 22, 2025, 04:00 ET EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
downstream payments, for a total potential consideration of up to EUR 1 billion. ImCheck Therapeutics is a private French biotechnology company pioneering next-generation immuno-oncology therapies. EQT Life Sciences has backed ImCheck since 2017 and has
More news about: EQT
Oct 22, 2025, 03:45 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Oct 22, 2025, 02:00 ET ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase
More news about: ACM Biolabs
Oct 21, 2025, 10:00 ET Exosome Technology Licensed to PranaX Published in Nature Communications
HOUSTON, Oct. 21, 2025 /PRNewswire/ -- PranaX Corporation, a leading biotechnology company specializing in regenerative biologics, has announced that a study concerning the exosome manufacturing technology exclusively licensed
More news about: PranaX
Oct 21, 2025, 09:20 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
identifying genetically modified cell lines to address hard to treat diseases while developing targeted cell-based treatments through innovative biotechnology partnerships. Back in June 2025, Avant announced plans to create a new company to house a joint venture, partnership,
More news about: Equity Insider
Oct 21, 2025, 09:00 ET The Galien Foundation Hosts 2025 Galien Week of Innovation to Showcase Advancements in Research, Diagnosis, and Treatment
This virtual webinar will bring together the nominees for the Best Biotechnology Product category, allowing participants to explore and examine the latest innovations in the biotechnology space.
More news about: The Galien Foundation
Oct 21, 2025, 09:00 ET HighVista Strategies Raises $270 Million for Oversubscribed Venture Capital Fund
strategies span private markets, including private credit, lower middle market private equity and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-strategy alternatives. Important Disclosure
More news about: HighVista Strategies LLC
Oct 21, 2025, 08:30 ET Halozyme to Report Third Quarter 2025 Financial and Operating Results
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Oct 21, 2025, 08:30 ET Improving Translational Research and Clinical Trials with Digital Pathology, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 21, 2025, 08:30 ET Beyond the bench: The advantages of GMP over USP compounding in early phase development, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 21, 2025, 08:30 ET CMC Development Strategies to Prevent Rework and Delays, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 21, 2025, 08:30 ET Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I
SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation
More news about: Roberts Communications
Oct 21, 2025, 08:30 ET Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
CSL (ASX: CSL; USOTC: CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza,
More news about: CSL Seqirus
Oct 21, 2025, 08:17 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial
More news about: Hagens Berman Sobol Shapiro LLP
Oct 21, 2025, 08:05 ET Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
PLYMOUTH MEETING, Pa., Oct. 21, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Oct 21, 2025, 08:00 ET Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho
Oct. 21, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company") and global biotechnology firm, Austrianova, today announced the official launch of their joint venture, Klothonova LLC, and its groundbreaking Klotho development program.
More news about: Avant Technologies Inc.
Oct 21, 2025, 08:00 ET Antheia Appoints Eric d'Esparbes as Chief Financial Officer
him to the team." d'Esparbes brings three decades of experience as a senior finance executive across the pharmaceutical, biotechnology, diagnostics, and energy industries. He has a proven track record building and leading finance organizations for companies with multi-billion-dollar
More news about: Antheia
Oct 21, 2025, 08:00 ET Boundless Futures Foundation grants $90,000 for Q3 to female company founders committed to both growth and good
sweeteners; a center providing creative programming for teens; and a company that is a pilot-scale biomanufacturing plant that helps food and agriculture biotechnology companies successfully scale precision fermentation. Since its inception in late 2023, Boundless Futures Foundation has awarded
More news about: Boundless Futures Foundation
Oct 21, 2025, 07:00 ET HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
About HanchorBio Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TWO), a global biotechnology company specializing in immuno-oncology, is led by an experienced team of pharmaceutical industry veterans with a proven track record of success
More news about: HanchorBio Inc.
Oct 21, 2025, 06:59 ET Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Oct 21, 2025, 06:00 ET Danaher Reports Third Quarter 2025 Results
Impairment charges related to technology and other intangible assets in the Biotechnology segment recorded in both the three and nine-month periods ended September 26, 2025 ($86 million pretax as reported in this line item, $58 million
More news about: Danaher Corporation